A Study of Extended Total Mesopancreas Excision(eTME) for Pancreatic Head Adenocarcinoma.

Pancreas Adenocarcinoma Clinical Trial

Official title:

Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04147403
• Other study ID #: ETMEFP_LYB_2019
• Status: Recruiting
• Start date: January 1, 2008
• Est. completion date: October 31, 2020

Study information

• Verified date: October 2019
• Source: Shanghai Jiao Tong University School of Medicine
• Contact: Yingbin Liu, Ph.D.
• Phone: +8613918803900
• Email: laoniulyb[@]163.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The study of extended total mesopancreas excision(eTME) for pancreatic head adenocarcinoma is a retrospective multicenter cohort, collecting medical records and follow-up data of patients who underwent radical resection with pancreatic head adenocarcinoma.

Description:

The objectives of the study are as follows:

1. To evaluate the perioperative safety of extended total mesopancreas excision(eTME) for patients who diagnosed with resectable pancreatic head adenocarcinoma.

2. To demonstrate the prognosis of extended total mesopancreas excision(eTME) for patients who diagnosed with resectable pancreatic head adenocarcinoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: October 31, 2020
• Est. primary completion date: October 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Patients with pancreatic head adenocarcinoma who underwent curative-intent resection.

2. Patients with accessible medical records

Exclusion Criteria:

1. Patients with unknown chemotherapy sequence or status

2. Patients with history of previous malignant tumors

3. Patients with distant metastases

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreas Adenocarcinoma

Locations

Country	Name	City	State
China	Changhai Hospital Affiliated to Naval Medical University	Shanghai	Shanghai
China	Ruijin Hospital,Affiliated to Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai
China	Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine	Shanghai	Shanghai
China	Zhongshan Hospital, Fudan University	Shanghai	Shanghai

Sponsors (3)

Lead Sponsor	Collaborator
Shanghai Jiao Tong University School of Medicine	Ruijin Hospital, Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	The overall survival data were defined by (date of death)-(date of first diagnosis).The survival status of patients were retrieved from follow-up.	5 years
Secondary	Disease free survival	The overall survival data were defined by (date of recurrence/progression)-(date of surgery).During follow-up period, abdominal enhanced CT, chest X-ray, tumor markers and routine blood tests were carried out to evaluate recurrence/progression.	5 years